Relay Therapeutics Amends ATM Offering; Files Q2 2026 Results

What Happened
Relay Therapeutics, Inc. announced on August 6, 2026 that it amended its common stock sales agreement with TD Securities (USA) LLC (TD Cowen) to increase its “at‑the‑market” (ATM) program from $250,000,000 to $462,978,049. The company also furnished a press release reporting its financial results for the quarter ended June 30, 2026 (Exhibit 99.2).

Key Details

• Amendment date: August 6, 2026; sales agent: TD Securities (USA) LLC (TD Cowen).
• ATM program size increased from $250,000,000 to $462,978,049.
• Shares sold to date under the program: approximately $162,978,049.
• New prospectus supplement covers up to $212,978,049 of additional Common Stock to be sold from time to time.
• TD Cowen will be paid up to 3.0% of gross proceeds for sales and may suspend sales; the company agreed to customary indemnification and contribution terms.
• Legal opinion from Goodwin Procter LLP regarding the additional shares is included as Exhibit 5.1.

Why It Matters
The amended ATM program gives Relay Therapeutics a larger, on‑demand way to raise capital by selling shares into the market, which can fund operations or programs without a single large underwritten offering. For investors, this increases the company’s flexibility to raise cash but also implies potential future dilution if and when shares are sold. The company is not obligated to sell shares and can pause sales, and TD Cowen will receive transaction fees up to 3% of proceeds. The filing also includes the company’s Q2 2026 results via a press release (no specific financial figures were included in the 8‑K text).